Rifamycin Antibacterial Drug Class List

Drugs in Drug Class: Rifamycin Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	AB	RX	Yes	Yes	8,829,017
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes	10,703,763
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	AB	RX	Yes	Yes	10,314,828
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	AB	RX	Yes	Yes	8,642,573
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes	8,741,904		Y	Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	AB	RX	Yes	Yes	10,703,763

Market dynamics and patent landscape for Rifamycin antibacterial drugs

Last updated: June 16, 2026

Rifamycin antibacterials span decades-old antibiotics (rifampin/rifampicin, rifabutin, rifapentine) and remain commercially anchored by tuberculosis (TB) programs and difficult-to-treat infections that require rifamycin-based combinations. Patent exposure today is dominated by: (1) granular, often late-life secondary patents on formulations, combinations, and dosing regimens; (2) brand-specific exclusivities and Orange Book listing structures; and (3) new pipeline entrants in rifamycin-resistant TB and long-acting or optimized oral regimens. For most legacy rifamycins, core composition-of-matter protection is largely expired in key markets; the enforceable estate shifts to manufacturing, polymorphs, process claims, and method-of-use claims tied to specific patient populations or regimen schedules.

---

Which rifamycin antibacterials drive the market today, and what are the commercial fault lines?

Featured snippet: Rifamycin sales remain tied to TB procurement cycles, stewardship constraints, and combination-formulation adoption. Market share and pricing power concentrate where fixed-dose combinations and regimen adherence are embedded in national TB guidelines.

Rifamycin antibacterial categories break down into two commercialization engines.

Tuberculosis core engine

Rifamycins are backbone drugs for active TB and latent TB regimens in combination. Commercial dynamics are shaped by:

• Government and global procurement (e.g., WHO-led programs and national TB control budgets)
• Tender-driven pricing and switching costs between suppliers
• Guideline lock-in for specific dosing frequencies and duration

Non-tuberculosis use engine

Rifamycin use outside TB depends on:

• Specialty indications (e.g., nontuberculous mycobacterial disease, prosthetic device infections in some settings)
• Stewardship policies and resistance monitoring
• Availability of alternative agents in the same therapeutic setting

Key commercial fault lines

• Guideline timing vs. patent timing: When a dosing regimen changes in guidelines, the relevant patent estate often shifts from core drug to regimen-formulation and method-of-use claims.
• Combination adoption: Fixed-dose combinations and regimen packs create a narrower “claim-to-supply” mapping than single-entity generics.
• Resistance economics: Rifamycin resistance reduces volume but increases the value of next-generation options and optimized salvage regimens.

---

How do rifamycin patent estates differ by drug: rifampin, rifapentine, and rifabutin?

Featured snippet: Core chemical patents on older rifamycins have largely lapsed; present enforceability is concentrated in secondary patents on polymorphs, solvates, formulation composition, process steps, and regimen-specific method-of-use.

Rifampin (rifampicin)

• Dominant protection historically centered on composition-of-matter and crystalline forms.
• Present enforcement typically shifts to:
  • Formulation patents (e.g., capsules vs. tablets; specific excipient systems)
  • Manufacturing/process claims (impurity profiles, crystallization control)
  • Regimen-linked method-of-use claims where a specific dosing schedule is claimed

Rifabutin

• Market is smaller than rifampin but tied to specific indications (notably mycobacterial disease) and combination use patterns.
• Estate often emphasizes:
  • Formulation and manufacturing controls
  • Method-of-use claims in defined therapeutic contexts

Rifapentine

• Rifapentine has been a focus for optimized LTBI and active TB regimen strategies using longer-interval dosing.
• Secondary patents tend to cluster around:
  • Tablet formulations optimized for dissolution and bioavailability
  • Dosing regimens (weekly or extended-interval schedules)
  • Combination packs/regimens where claims track regimen composition and patient eligibility

---

What patents protect rifampin products in the Orange Book, and what typically remains enforceable after primary expiry?

Featured snippet: Most rifampin brand exclusivity is already past; Orange Book listings today frequently reflect formulation and method-of-use patents rather than new chemical entities.

The Orange Book structure for rifampin products commonly maps to:

• Listed patents tied to specific dosage forms (immediate-release tablets, capsules, or specialty formulations)
• Listed patents tied to specific therapeutic uses or dosing schedules
• Manufacturing patents that can complicate “same API, different process” generic entry design

Practical estate patterns for rifamycin generics

• If the Orange Book lists formulation or method-of-use patents, generic applicants often file:
  • Para. IV certifications to listed patents they challenge
  • Design-around versions that try to avoid the claim scope
• If a listed patent is a method-of-use claim, generic entry can hinge on how labeling and prescribed dosing are structured, not only formulation chemistry.

---

When does generic entry become realistic for rifamycin drugs under Paragraph IV dynamics?

Featured snippet: Generic entry timing is driven by the latest relevant listed patent expiration and exclusivity blocks (including any pediatric exclusivity or application-specific exclusivities). For rifamycins, the “latest-to-expire” patents are usually secondary formulation or regimen claims.

How timing works in practice

• The relevant trigger is not just chemical patent expiration.
• For each brand, investors need:
  • Latest listed Orange Book patent expiration date (and any pediatric exclusivity extension)
  • Whether patents are method-of-use or formulation
  • Whether any settlement agreement bars entry beyond the patent expiration

Typical rifamycin entry playbook

• Generic applicants file Paragraph IV to one or more listed patents.
• Litigation usually targets:
  • Claim construction for formulation/manufacturing details
  • Whether design-around avoids infringement
• Settlements frequently delay launch but can also restrict launch labeling or specific dosage strengths.

---

What patent litigation affects rifamycin antibiotics: who challenges whom and on what claims?

Featured snippet: Rifamycin litigation is concentrated around Orange Book-listed patents for formulation, dosing regimens, and manufacturing. Disputes typically arise where generics dispute listed patent validity or non-infringement.

Litigation themes that recur in rifamycin cases

• Formulation patent disputes: alleged infringement based on excipient selection, dissolution behavior, or polymorph control.
• Manufacturing/process claims: dispute over whether the generic’s crystallization steps and impurity limits match the asserted process.
• Method-of-use disputes: disputes about whether prescribing the generic under a specific dosing schedule infringes.

What to track for litigation risk scoring

• Whether the asserted patents are “listed” Orange Book patents (not just related technical patents)
• Whether the case targets regulatory entry and labeling (method-of-use) vs manufacturing design-around (process/formulation)
• Settlement constraints that affect the scope of launch and labeling language

---

How strong is the patent estate for rifamycin antibacterials today (and what claim types dominate enforceability)?

Featured snippet: Estate strength shifts from composition-of-matter to secondary patents that are narrower but can be strategically enforceable via Orange Book listing and method-of-use labeling.

Claim types that dominate enforceability

• Polymorph/solid state claims: crystal forms, solvates, or specific solid-state properties.
• Formulation claims: excipient systems, coatings, controlled release behavior (where applicable).
• Process claims: crystallization, purification, drying conditions, impurity thresholds.
• Method-of-use claims: defined patient groups, dosing schedules, and combination regimens.

Why this matters for design-around

• Generics can often switch to different polymorphs or manufacturing routes, but:
  • Solid-state and process claims can be hard to avoid if constrained by functional properties
  • Method-of-use claims can constrain labeling and practical prescribing behavior

---

What formulations are protected for rifamycin antibiotics, and where are the design-around bottlenecks?

Featured snippet: The highest design-around bottlenecks are typically solid-state and process-related patents that map to measurable properties, and method-of-use claims that map to labeling.

Rifamycin formulation protection patterns

• Tablets/capsules with specific dissolution or bioavailability profiles
• Film coatings or enteric properties (where claimed)
• Solid form constraints that tie to stability and bioequivalence
• Manufacturing impurity controls that support safety specifications and claim scope

Bottlenecks

• Bioequivalence vs claim scope: A generic may match pharmacokinetics but still fall within formulation or solid-state claims.
• Functional limitation claims: If patents claim “a solid form having X property,” design-around requires demonstrated divergence, not just a different route.

---

What method-of-use patents for rifamycin regimens are likely to matter for generic labeling and launch?

Featured snippet: Regimen-specific method-of-use patents can block launch by forcing labeling design constraints or by triggering infringement when the branded regimen is adopted in practice.

Method-of-use risk areas

• LTBI dosing regimens: weekly or extended-interval dosing strategies are common targets.
• Active TB regimen schedules: duration and combination specifics create narrow claim scope but can be enforceable if labeling mirrors the claimed regimen.
• Patient population qualifiers: age, comorbidity, or treatment-history qualifiers can shift infringement analysis.

Litigation consequence

If a generic applicant’s label must omit or alter the claimed regimen, practical uptake may fall even if the product is “therapeutically equivalent” in pharmacology.

---

What biosimilar risk exists in rifamycin antibacterials?

Featured snippet: Biosimilar risk is not a core issue for rifamycin antibacterials because these are small-molecule antibiotics, not biologics.

What replaces “biosimilar” dynamics

• Generics and authorized generics
• Rx-to-OTC shifts do not apply to rifamycins
• New fixed-dose combinations that change regimen economics

---

How do rifamycin fixed-dose combinations change the patent landscape and licensing economics?

Featured snippet: Fixed-dose combinations shift patent risk toward combination claims, regimen-specific labeling, and formulation co-optimization rather than just individual API patents.

Patent estate impact

• Combination patents may claim:
  • The co-formulated ratio of rifamycin with another agent
  • A specific dosing schedule and patient selection
• Even when each component’s core patents are expired, combination patents can be the “last barrier” if listed.

Licensing economics

• Brand owners can structure settlements where:
  • Generics get permission to launch outside asserted regimen scope
  • Authorized generic pathways reduce litigation exposure for both sides
• Public procurement frameworks can reward reliable supply and compliance history, affecting negotiated licensing leverage.

---

How do FDA regulatory milestones intersect with rifamycin patent timelines?

Featured snippet: FDA approval timing under ANDA and labeling changes can collide with patent expiration and Orange Book listing windows, shaping whether a launch is blocked or allowed.

Regulatory milestones to model

• ANDA submission and certification timing (Paragraph IV)
• Patent expiration and exclusivity windows (including pediatric extensions)
• Labeling negotiations that affect method-of-use infringement
• Launch readiness timing based on manufacturing validation

Practical effect

• A Paragraph IV ANDA can be “ready” legally, but launch can still be constrained by:
  • Settlement injunction-like terms
  • Patent still in force at the moment of marketing
  • Labeling restrictions that effectively limit uptake

---

What generic entry risks exist for rifamycin drugs across key geographies?

Featured snippet: Geographic risk varies less by the molecule and more by Orange Book listing coverage, litigation strategy, and enforcement capacity for formulation and method-of-use patents.

Key geography patterns

• US: Orange Book listing and Hatch-Waxman procedure drive launch and litigation.
• EU/UK: Market authorization relies on national patent enforcement; “skinny labels” can be constrained by local practice.
• Canada/Australia: Patent enforcement and regulatory linkage structures vary, altering the time-to-market risk.

---

Which companies are positioned to supply rifamycin generics, and who tends to hold the strongest secondary estates?

Featured snippet: Generic supply is typically broad for older rifamycins; stronger leverage typically sits with brand owners that list multiple secondary patents across formulations and dosing regimens.

Who holds leverage

• Brand owners and their patent-prosecution arms that maintain multi-layer listings.
• Companies with manufacturing capabilities that can target specific solid-state or process design-around pathways.

What matters for competitive strategy

• Whether a competitor plans a “label-constrained” launch to avoid method-of-use infringement
• Whether they can demonstrate non-infringement on formulation/process without losing bioequivalence
• Whether they accept a delayed launch in exchange for settlement certainty

---

How does rifamycin patent coverage compare with other TB backbone antibiotics (e.g., isoniazid and pyrazinamide)?

Featured snippet: Rifamycins tend to have stronger enforceability around solid state, formulation, and regimen-linked patents because they are central to modern LTBI and TB regimen schedules where dosing frequency matters.

Comparative estate dynamics

• Older first-line TB drugs also have expired primary patents in most markets.
• The difference is that rifamycins remain tightly coupled to regimen design and fixed-interval dosing strategies, which keeps secondary patents commercially relevant.

---

Key patent landscape map: what claim types and dates typically control outcomes for rifamycin launches?

Featured snippet: For most rifamycin products, the “last-to-expire” assets are secondary patents mapped to the Orange Book and tied to the marketed dosage form or regimen.

Modeling framework for investors and counsel

• Build a product-by-product table with:
  • Orange Book listed patents (numbers and expiration dates)
  • Patent family members (US and major foreign filings when available)
  • Claim type (composition, formulation, process, method-of-use)
  • Whether the patent is asserted in litigation or subject to Paragraph IV challenges
• Overlay:
  • Regulatory exclusivity periods
  • Settlement-based launch restrictions
  • Expected generic manufacturing and labeling design-around constraints

What “strong estate” usually looks like in rifamycins

• Multiple listed patents with different expiration dates, spanning:
  • Solid-state/formulation and method-of-use
  • At least one patent that is hard to design around without altering the product’s physical or dosing characteristics

---

Key Takeaways

• Rifamycin markets are dominated by TB regimen procurement cycles and fixed-dose regimen adoption, which keeps secondary patents commercially relevant even after primary composition protection lapses.
• Patent enforceability is now concentrated in formulation, solid state, manufacturing/process, and method-of-use claims tied to marketed dosing schedules and labeling.
• Generic entry timing is primarily a function of the latest Orange Book listed patent expiration and exclusivity blocks, plus settlement terms after Paragraph IV challenges.
• Biosimilar risk is not applicable; competitive risk is instead centered on ANDA-based generics, authorized generics, and combination-regimen patent barriers.

---

FAQs

1) Do rifampin generics face method-of-use labeling restrictions even after Orange Book primary patents expire?

Often yes, when Orange Book-listed method-of-use patents remain in force and are tied to specific dosing regimens that must be reflected or omitted in the generic label.

2) Are solid-state polymorph patents a common driver of rifamycin generic non-infringement disputes?

Yes. Solid-state claims can be difficult to design around because they can be tied to measurable properties that affect stability and performance.

3) How do fixed-dose rifamycin combinations change Paragraph IV litigation strategy?

They shift disputes toward combination formulation and regimen-specific claims, raising the importance of co-formulation equivalence and labeling scope.

4) What regulatory events most influence rifamycin launch timing in Hatch-Waxman cases?

The ANDA certification decisions, Orange Book listed patent expiration timing, and any settlement-driven labeling constraints that affect practical market entry.

5) Does rifamycin patent strength vary materially across rifampin vs rifapentine?

Yes. Rifapentine is more tightly tied to extended-interval regimen strategies, so regimen and formulation secondary patents can remain more commercially constraining than in older single-agent use patterns.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. WHO. (n.d.). Tuberculosis (TB) fact sheets and guidance materials. World Health Organization. https://www.who.int/health-topics/tuberculosis